Treatment Approaches to Major Depressive Disorder Relapse
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Anecdotal reports concerning mood disorder patients suggest restarting drug treatment in patients who prematurely discontinue it may be associated with a diminished chance of response upon rechallenge. We evaluated the likelihood of response to reinitiation of fluoxetine treatment in patients relapsing after switching to placebo during a long-term efficacy study of two different dosing regimens of fluoxetine. Method: Patients who met the DSM-IV major depressive disorder criteria with modified HAMD17 scores ≧18 and CGI-Severity scores ≧4 were treated with open-label 20 mg/day fluoxetine for 13 weeks in a multicenter US study. Responders (n = 501) were randomized to placebo, 20 mg fluoxetine daily, or 90 mg enteric-coated fluoxetine weekly for 25 weeks of double-blind continuation treatment. Patients relapsing during the continuation phase were offered 25 weeks of double-blind rescue treatment during which the study medication dose was increased as follows: (1) patients on placebo had treatment with fluoxetine 20 mg/ day reinitiated; (2) patients on fluoxetine 20 mg/day had their dose increased to 40 mg/day, and (3) patients on a 90-mg weekly dose had their dose increased to 90 mg twice a week. Only the results of the rescue phase for the group who relapsed while on continuation treatment with placebo are reported here. Analyses included percentage of responders (50% reduction of modified HAMD17 and CGI-Severity ≤2) and assessments of change from baseline to endpoint (HAMD, CGI-Severity). Safety measures included assessment of vital signs, laboratory measures, and treatment-emergent adverse events. Results: Of 122 patients assigned to placebo, 57 (47%) relapsed during continuation treatment. Fifty-five (96%) of these elected to enter double-blind rescue treatment. Overall, patients who relapsed upon switching to placebo responded well to reinitiation of fluoxetine (62%). The mean modified HAMD17 score decreased from 20 to less than 9 and was maintained for up to 6 months. Thirty-eight percent of patients either did not respond or initially responded but again relapsed after reinitiation of medication. Conclusion: This study suggests that patients who, after an initial response to fluoxetine, relapse upon switching to placebo have a relatively high probability of responding to the reinitiation of fluoxetine treatment. These results challenge the view that the efficacy of an agent prematurely discontinued is diminished when such an agent is restarted. They also generally support reinitiation of the same antidepressant as a ‘first-line’ treatment strategy in patients who relapsed after stopping a previously effective antidepressant.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“prospective studies have shown that more negatively biased cognitive schemas are associated with a worse clinical course and more severe symptomatology [65].”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [65]
Citations
Cites
Stewart, J. W., Quitkin, F. M., McGrath, P. J., Amsterdam, J., Fava, M., Fawcett, J., Reimherr, F., Rosenbaum, J., Beasley, C., & Roback, P. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.4.334 · Cited by 113
Pharmacotherapy of depressive disorders
Centres, W. M. H. C. (1989) · Journal of Affective Disorders · doi:10.1016/0165-0327(89)90043-8 · Cited by 60
Reducing Relapse in Depressed Outpatients with Atypical Features: A Pilot Study
Jarrett, R. B., Kraft, D., Schaffer, M., Witt-Browder, A., Risser, R., Atkins, D. H., & Doyle, J. (2000) · Psychotherapy and Psychosomatics · doi:10.1159/000012401 · Cited by 48
Management of Major Depression in the Primary Care Setting
Mischoulon, D., McColl-Vuolo, R., Howarth, S., Lagomasino, I. T., Alpert, J. E., Nierenberg, A. A., & Fava, M. (2001) · Psychotherapy and Psychosomatics · doi:10.1159/000056233 · Cited by 25
Cited by
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,520
McMahon, F. J., Buervenich, S., Charney, D., Lipsky, R., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Papanicolaou, G. J., Laje, G., Fava, M., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/503820 · Cited by 474
Six-Year Outcome of Cognitive Behavior Therapy for Prevention of Recurrent Depression
Fava, G. A., Ruini, C., Rafanelli, C., Finos, L., Conti, S., & Grandi, S. (2004) · American Journal of Psychiatry · doi:10.1176/ajp.161.10.1872 · Cited by 392
Can long-term treatment with antidepressant drugs worsen the course of depression?
Fava, G. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0204 · Cited by 223
Chouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
“Thirty-eight percent of patients either did not respond or initially responded but again relapsed after reinitiation of medication (Fava et al., 2002).”
Post, R. M., Leverich, G. S., Nolen, W. A., Kupka, R. W., Altshuler, L. L., Frye, M. A., Suppes, T., McElroy, S., Keck, P., Grunze, H., et al. (2003) · Bipolar Disorders · doi:10.1046/j.1399-5618.2003.00065.x · Cited by 142
Rational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95
Perahia, D. G., Gilaberte, I., Wang, F., Wiltse, C. G., Huckins, S. A., Clemens, J. W., Montgomery, S. A., Montejo, A. L., & Detke, M. J. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.4.346 · Cited by 94
“1) was similar to that of previous relapse-prevention studies (Fava et al, 2002; Schmidt et al, 2002).”
ResultVan Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Fava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84
Treatment of Recurrent Depression: A Sequential Psychotherapeutic and Psychopharmacological Approach
Fava, G. A., Ruini, C., & Sonino, N. (2003) · CNS Drugs · doi:10.2165/00023210-200317150-00005 · Cited by 70
A Comparative Meta-Analysis of Clinical Global Impressions Change in Antidepressant Trials
Spielmans, G. I., & McFall, J. P. (2006) · Journal of Nervous & Mental Disease · doi:10.1097/01.nmd.0000244554.91259.27 · Cited by 64
Preventing Recurrent Depression: Long-Term Treatment for Major Depressive Disorder
Blier, P., Keller, M. B., Pollack, M. H., Thase, M. E., Zajecka, J. M., & Dunner, D. L. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0307e06 · Cited by 54
Major Depressive Disorder with Anger: A Bipolar Spectrum Disorder?
Benazzi, F. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000073026 · Cited by 52
Antidepressant Withdrawal and Rebound Phenomena
Henssler, J., Heinz, A., Brandt, L., & Bschor, T. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0355 · Cited by 50
The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem
Fava, G. A., Cosci, F., Guidi, J., & Rafanelli, C. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507227 · Cited by 48
Fochtmann, L. J., & Gelenberg, A. J. (2005) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.3.1.34 · Cited by 44
Tolerance in antidepressant treatment
Baldessarini, R. J., Ghaemi, S. N., & Viguera, A. C. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000063641 · Cited by 42
Antidepressant Dose Reduction and the Risk of Relapse in Major Depressive Disorder
Papakostas, G. I., Perlis, R. H., Seifert, C., & Fava, M. (2007) · Psychotherapy and Psychosomatics · doi:10.1159/000104702 · Cited by 38
Management of depression relapse: Re-initiation of duloxetine treatment or dose increase
Fava, M., Detke, M. J., Balestrieri, M., WANG, F., Raskin, J., & David, P. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.06.005 · Cited by 39
Treatment of recurrent depression
Fava, G. A., Park, S. K., & Sonino, N. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.11.1735 · Cited by 36
Inter‐episode mood lability in mood disorders: residual symptom or natural course of illness?
Benazzi, F. (2004) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2004.01289.x · Cited by 34
New Formulations of Existing Antidepressants: Advantages in the Management of Depression
Norman, T. R., & Olver, J. S. (2004) · CNS Drugs · doi:10.2165/00023210-200418080-00003 · Cited by 32
Conflict of Interest in Psychopharmacology: Can Dr. Jekyll Still Control Mr. Hyde?
Fava, G. A. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000074433 · Cited by 24
Management of Recurrent Depression in Primary Care
Fava, G. A., Ruini, C., & Sonino, N. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000067189 · Cited by 20
Faravelli, C., Cosci, F., Ciampelli, M., Scarpato, M. A., Spiti, R., & Ricca, V. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000068689 · Cited by 22
Failure to Respond after Reinstatement of Antidepressant Medication: A Systematic Review
Bosman, R. C., Waumans, R. C., Jacobs, G. E., Oude Voshaar, R. C., Muntingh, A. D. T., Batelaan, N. M., & van Balkom, A. J. L. M. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491550 · Cited by 21
Tolerance to antidepressant treatment may be overcome by ketoconazole. Report of two cases
Sonino, N., & Fava, G. A. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00089-4 · Cited by 19
Mallinckrodt, C., Chuang‐Stein, C., McSorley, P., Schwartz, J., Archibald, D. G., Perahia, D. G., Detke, M. J., & Alphs, L. (2007) · Pharmaceutical Statistics · doi:10.1002/pst.234 · Cited by 18
Drug Class Review: Second-Generation Antidepressants
Gartlehner, G., Hansen, R. A., Reichenpfader, U., Kaminski, A., Kien, C., Strobelberger, M., Noord, M. V., Thieda, P., Thaler, K. J., & Gaynes, B. N. (2011) · Cited by 17
Antidepressant‐Induced Manic Conversion: A Developmentally Informed Synthesis of the Literature
Lim, C. J., Leckman, J. F., Young, C., & Martin, A. (2005) · International review of neurobiology · doi:10.1016/s0074-7742(04)65002-1 · Cited by 16
Preventing Recurrent Depression: Long-Term Treatment for Major Depressive Disorder
(2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0420 · Cited by 14
Stratégies thérapeutiques des troubles de l’humeur
Vandel, P., Rebière, V., & Sechter, D. (2004) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/j.emcps.2004.10.001 · Cited by 7
Current situation of long-term treatment of depression.
Ruiloba, J. V. (2007) · Actas Españolas de Psiquiatría · Cited by 6
Reconnaître les symptômes psychiatriques iatrogènes liés aux antipsychotiques
Demily, C., Chouinard, V., & Chouinard, G. (2010) · L Encéphale · doi:10.1016/j.encep.2010.01.003 · Cited by 5
An Editor’s Journey Ends, but the Journal’s Mission Continues
Fava, G. A. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524654 · Cited by 5
TRATAMENTO FARMACOLÓGICO DISPONÍVEL NO BRASIL DA DEPRESSÃO MAIOR: UMA REVISÃO LITERÁRIA
Fronza, D., Woiciekoski, J. V. B., & Lise, A. M. R. (2019) · Revista Thêma et Scientia · Cited by 3
Stratégies thérapeutiques des troubles de l'humeur
Vandel, P., Rebière, V., & Sechter, D. (2005) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(05)38525-7 · Cited by 3
Majkic, N., & Taylor, D. M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251364388 · Cited by 3
Гарибова, Т. Л., Крайнева, В. А., Вальдман, Е. А., Гудашева, Т. А., Олеговна, К. С., & Середенин, С. Б. (2018) · Reviews on Clinical Pharmacology and Drug Therapy · doi:10.17816/rcf16128-33 · Cited by 1
Yoshimura, R., Okamoto, N., Igata, R., & Ikenouchi, A. (2021) · ALPHA PSYCHIATRY · doi:10.5152/alphapsychiatry.2021.21750 · Cited by 1
Santone, G., Bellantuono, C., & Psichiatrica, C. (2009) · Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology
Bibliography for M ajor D epressive D isorder
(2005) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.3.1.51
Treatment of depression after acute phase of the disorder
Knežević, V. (2022) · Galenika Medical Journal · doi:10.5937/galmed2203029k
Les manifestations cliniques associées à la toxicité comportementale
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00003-0
Metadata
- Authors
- Fava, M., Schmidt, M. E., Zhang, S., Gonzales, J., Raute, N. J., & Judge, R.
- Affiliations
- Eli Lilly (United States) (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2002
- Volume
- 71
- Issue
- 4
- Pages
- 195-199
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W196332875
- Cited by
- 44
- References
- 4
- Citations by year
- 2025: 1 · 2024: 1 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 2 · 2014: 1
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- major depressive disorder, relapse, fluoxetine, drug rechallenge, treatment discontinuation, salvage therapy, antidepressant efficacy, dose escalation, treatment-emergent adverse events, HAM-D-17, relapse prevention
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Major Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Fluoxetine, Humans, Male, Middle Aged, Recurrence, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.